2023 Hematology Highlights (Attendee Information)

Hilton Omaha
1001 Cass Street, Omaha, NE 68102

As a registered participant, you are entitled to one self-park ticket at the Hilton Omaha. Please be sure to bring your parking ticket with you and present this at the conference registration desk for validation.

Read the UNMC CCE Disclosure Declaration Policy 

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

• Christopher D’Angelo, MD
  • Advisory Board: AbbVie, Inc., Seagen, Inc., TG Therapeutics
• Faith Davies, MD
  • Advisory Board: AbbVie, Inc.; Amgen; Celgene Corporation (A Bristol-Myers
    Squibb Company); GSK; Janssen Biotech, Inc. (administered by Janssen Scientific LLC); Takeda Pharmaceuticals USA, Inc.; Oncopeptides; Sanofi
  • INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:  Off-label drug discussion of new multiple myeloma therapies presented at ASH 22
• Kathryn Hassell, MDConsultant: Pfizer Inc.
  • Research Funding: Bausch Health; Salix Pharmaceuticals; Takeda Pharmaceuticals USA, Inc.
• Vivian Oehler, MD
  • Consultant: Pfizer Inc.
  • Research Funding: Novartis Pharmaceuticals Corporation; Pfizer Inc.

• Wendy Stock, MD
  • Consultant: Amgen: GSK; Jazz Pharmaceuticals; Kite Pharma, Inc. (A Gilead Company); Kura Oncology, Inc.; Newave; Syndax; Pfizer Inc.
  • INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:  Off-label drug discussion of Venetoclax use in ALL
• William Wierda, MD, PhD
  
  • Contracted Research: AbbVie, Inc.; Acerta Pharma (A Member of the AstraZeneca Pharmaceuticals Group); AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Celgene Corporation (A Bristol-Myers Squibb Company); Cyclacel Pharmaceuticals, Inc.; Genentech, Inc. (A Member of the Roche Group); Gilead Sciences, Inc.; GSK; Janssen Biotech, Inc. (administered by Janssen Scientific Affairs LLC); Juno Pharmaceuticals; Kite Pharma, Inc. (A Gilead Company); Loxo@Lilly; Novartis Pharmaceuticals Corporation; Oncternal Therapeutics, Inc.; Pharmacyclics (an AbbVie Company); Viracta; Viridian; Xencor
• Amer Zeidan, MBBS, MHS
  • Clinical Trial Committee: AbbVie, Inc.; Bristol-Myers Squibb; Celgene Corporation (A Bristol-Myers Squibb Company); Geron; Gilead Sciences, Inc.; Kura Oncology, Inc.; Novartis Pharmaceuticals Corporation
  • Consultant: AbbVie, Inc.; Agios Pharmaceuticals, Inc.; Amgen; Aprea Therapeutics; Astellas Pharma US, Inc.; BeyondSpring Pharmaceuticals; Boehringer-Ingelheim; Bristol-Myers Squibb; Cardiff Oncology; Cardinal Health; Celgene Corporation (A Bristol-Myers Squibb Company); Daiichi Sankyo; Geron; Gilead Sciences, Inc.; Incyte Corporation; Ionis Pharmaceuticals; Ipsen Biopharmaceuticals, Inc.; Janssen Biotech, Inc. (administered by Janssen Scientific Affairs LLC); Jazz Pharmaceuticals; Kura Oncology, Inc.; Merck & Co.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical; Pfizer Inc.; Seagen, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Pharmaceutical Co.; Takeda Pharmaceuticals USA, Inc.
  • Honoraria: AbbVie, Inc.; Agios Pharmaceuticals, Inc.; Amgen; Aprea Therapeutics; Astellas Pharma US, Inc.; BeyondSpring Pharmaceuticals; Boehringer-Ingelheim; Bristol-Myers Squibb; Cardiff Oncology; Cardinal Health; Celgene Corporation (A Bristol-Myers Squibb Company); Daiichi Sankyo; Geron; Gilead Sciences, Inc.; Incyte Corporation; Ionis Pharmaceuticals; Ipsen Biopharmaceuticals, Inc.; Janssen Biotech, Inc. (administered by Janssen Scientific Affairs LLC); Jazz Pharmaceuticals; Kura Oncology, Inc.; Merck & Co.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical; Pfizer Inc.; Seagen, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Pharmaceutical Co.; Takeda Pharmaceuticals USA, Inc.
  • Research Funding: AbbVie, Inc.; ADC Therapeutics America, Inc.; Amgen; Aprea Therapeutics; Astex Pharmaceuticals; AstraZeneca Pharmaceuticals; Boehringer-Ingelheim; Bristol-Myers Squibb; Cardiff Oncology; Celgene Corporation (A Bristol-Myers Squibb Company); Incyte Corporation; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical; Pfizer Inc.; Takeda Pharmaceuticals USA, Inc.
  • Travel Support: Cardiff Oncology; Novartis Pharmaceuticals Corporation; Pfizer Inc.

PLANNING COMMITTEE

The following has disclosed relevant financial relationships:

• Jared Matya, PharmD, BCOP
  • Advisory Board: AstraZeneca Pharmaceuticals, Genmab

The following have nothing to disclose:

• R. Gregory Bociek, MD, MSc, FRCP(C)*
• Heidi J. Keeler, PhD, RN, MSN/MBA
• Lori Maness-Harris, MD*
• Renee Paulin, MSN, RN, CWOCN
• Valeta Creason-Wahl, HMCC
• Bailey Wrenn, MA

*Faculty and planning committee member

The following materials (in PDF) are available for download until March 4, 2023. No part of these materials may be reproduced without permission.

• New Developments with Hemostasis and Thrombosis 
  Kathryn Hassell, MD
• Myelodysplastic Syndromes: Updates from ASH 2022 Annual Meeting
  Amer Zeidan, MBBS, MHS
• Myeloproliferative Neoplasms: What We Have Recently Discovered
  Vivian Oehler, MD
• Advances in Acute Myeloid Leukemias
  Wendy Stock, MD
• Multiple Myeloma: Updates from ASH 2022 Annual Meeting
  Faith Davies, MD
• Updates in Chronic Lymphocytic Leukemia
  William Wierda, MD, PhD
• Highlights in Lymphoma from 2022 ASH Annual Meeting
  Christopher D'Angelo, MD